Prosthetic Heart Valves

Vongpatanasin, Wanpen; Hillis, L. David; Lange, Richard A.

doi:10.1056/nejm199608083350607

Cited by 644 publications

(348 citation statements)

References 88 publications

Supporting

Mentioning

326

Contrasting

Unclassified

Order By: Relevance

“…317 Thrombotic occlusion of a prosthetic valve has an incidence of 0.5% to 6% per patient-year. [335][336][337][338][339] The risk of valve thrombosis is not linear and is more frequent early after replacement. Presentation of patients ranges from asymptomatic to cardiogenic shock.…”

Section: Recommendations For Long-term Prevention Ofmentioning

confidence: 99%

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

Giglia¹,

Massicotte²,

Tweddell³

et al. 2013

Circulation

269

245

View full text Add to dashboard Cite

Section: Recommendations For Long-term Prevention Ofmentioning

confidence: 99%

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

Giglia¹,

Massicotte²,

Tweddell³

et al. 2013

Circulation

269

245

View full text Add to dashboard Cite

“…Anticoagulant therapy is required in patients with a mechanical prosthetic heart valve to prevent stroke and systemic embolism, and to prevent valve thrombosis, which is associated with a 15% mortality rate [13,14]. Patients with a prosthetic mitral valve, a caged-ball valve, and two prosthetic heart valves are at highest risk for thromboembolic events [15]. Patients with a prosthetic aortic valve and two or more thromboembolic risk factors may be considered at moderate risk for thromboembolic events, whereas patients with a prosthetic aortic valve and less than two thromboembolic risk factors are at lowest risk.…”

Section: Discussionmentioning

confidence: 99%

Laparoscopic Cholecystectomy for Children with Repaired Tetralogy of Fallot with Valve Replacement on Anticoagulant: A Case Report and Anticoagulant Management

Barman¹

2014

J Cardiovasc Dis Diagn

View full text Add to dashboard Cite

A 7 year old boy with a history of repaired tetralogy of Fallot with aortic valve replacement was scheduled to undergo laparoscopic cholecystectomy. His significant history comprises of post cardiac surgery with warfarin anticoagulant. Perioperatively warfarin was converted to low molecular weight heparin and the patient underwent general endotracheal anaesthesia with caudal epidural anaesthesia for laparoscopic cholecystectomy. Anaesthesia induction, intraoperative course and postoperative period proceeded uneventfully and the patient quickly progressed to the preoperative level of functioning. The perioperative anticoagulant management in such patients of repaired tetralogy of Fallot with aortic valve replacement is reviewed.

show abstract

“…Glutaraldehyde has been widely used as a tissue fixative for these bioprosthetic valves and vascular grafts due to its ability to produce collagen crosslinking, reduce tissue antigenicity and sterilize the valves [27]. Bioprosthetic valves have a possibility of the prosthetic valve failure due to calcification, pannus formation and tissue degeneration; several reagents have been extensively investigated to inhibit them [5,22].…”

Section: Discussionmentioning

confidence: 99%

Short-Term Performance of Mitral Valve Replacement with Porcine Bioprosthetic Valves in Dogs

Takashima¹,

Soda

Tanaka

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Porcine bioprosthetic valves cross-linked with glutaraldehyde and polyepoxy compound were newly developed for mitral valve replacement (MVR) in dogs. Five beagle dogs were performed a left thoracotomy and underwent MVR using the porcine bioprosthetic valves during cardiopulmonary bypass (CPB). A vein catheter inserted into right atrium and a vent catheter inserted into the right ventricle to drain. The hemodynamic conditions of CPB were excellent during surgery. The left atrial pressure was measured before and after MVR; there was no significant difference and it was normal. Thrombosis and the prosthetic valve regurgitation were not observed one week after MVR. Pressure half time (PHT) prolonged significantly (P<0.05) from 31.40 ± 4.0 msec presurgery to 99.20 ± 19.4 msec at seven days after MVR, although it indicated the normal range as the bioprosthetic valve. The symptom of the prosthetic valve failure was not observed. This study indicated that the MVR using porcine bioprosthetic valves under CPB might have been effective in dogs as a short-term evaluation. KEY WORDS: bioprosthetic valve, canine cardiopulmonary bypass, mitral regurgitation, mitral valve replacement.

show abstract

Prosthetic Heart Valves

Cited by 644 publications

References 88 publications

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

Laparoscopic Cholecystectomy for Children with Repaired Tetralogy of Fallot with Valve Replacement on Anticoagulant: A Case Report and Anticoagulant Management

Short-Term Performance of Mitral Valve Replacement with Porcine Bioprosthetic Valves in Dogs

Contact Info

Product

Resources

About